Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

Titre officiel

Pharmacokinetics of Infliximab and Tumour Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

Sommaire:

Il s’agit d’une étude ouverte, prospective et observationnelle dont l’objectif principal est de caractériser le profil pharmacocinétique de l’infliximab chez les patients atteints d’une colite ulcéreuse aiguë sévère.

Description de l'essai

Primary Outcome:

• Inter-compartmental Difference in Infliximab Concentration

Secondary Outcome:

• Change in Proteome
• Change in Transcriptome
• Change in Robarts Histopathologic Index
• Change in Mayo Clinic Endoscopic Score

In Acute Severe Ulcerative Colitis (ASUC), drug exposure may be affected by intestinal protein loss leading to hypoalbuminemia and rapid clearance of infliximab (IFX). Importantly, 2 studies have associated the loss of IFX in stool with poor outcomes. Multiple observational studies have identified that patients with faster IFX clearance have worse clinical outcomes and higher rates of antidrug antibody formation. To better understand optimal dosing of IFX in ASUC, the pharmacokinetics of IFX in association with outcomes must be better defined in this setting.

Voir cet essai sur ClinicalTrials.gov